421595-81-5

Basic information

• Product Name: Imidazo[1,2-a]pyridin-7-amine (9CI)
• Synonyms: Imidazo[1,2-a]pyridin-7-amine (9CI);Imidazo[1,2-a]pyridin-7-amine;H-imidazo[1,2-a]pyridin-7-amine;7-Aminoimidazo[1,2-a]pyridine
• CAS NO: 421595-81-5
• Molecular Formula: C₇H₇N₃
• Molecular Weight: 133.15058
• Product Categories: AMINETERTIARY;Building Blocks;Imidazo[x,x-y]pyridine;organic building block
• Mol File: 421595-81-5.mol

Chemical Properties

• Appearance: /
• Density: 1.32±0.1 g/cm3(Predicted)
• Refractive Index: 1.696
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 8.98±0.50(Predicted)
• CAS DataBase Reference: Imidazo[1,2-a]pyridin-7-amine (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Imidazo[1,2-a]pyridin-7-amine (9CI)(421595-81-5)
• EPA Substance Registry System: Imidazo[1,2-a]pyridin-7-amine (9CI)(421595-81-5)

Safety Data

• Hazardous Substances Data: 421595-81-5(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
Imidazo[1,2-a]pyridin-7-amine (9CI) is used as a building block for the development of drugs in medicinal chemistry. Its chemical structure allows it to bond with biological targets, making it a promising candidate for the creation of new pharmaceuticals.
Used in Drug Design:
Imidazo[1,2-a]pyridin-7-amine (9CI) is used as a molecular scaffold in drug design. Its unique structure and bonding capabilities enable the development of novel compounds with potential therapeutic applications.
Note: Due to the limited information available on Imidazo[1,2-a]pyridin-7-amine (9CI), the above uses are based on its classification and the general properties of compounds within the imidazopyridine and aminopyridine families. Further research and detailed investigations are required to confirm its specific applications and properties.

InChI:InChI=1/C7H7N3/c8-6-1-3-10-4-2-9-7(10)5-6/h1-5H,8H2

Upstream product

• 421596-48-7 ethyl N-(imidazo[1,2-a]pyridin-7-yl)carbamate 
• 372147-49-4 imidazo[1,2-a]pyridine-7-carboxylic acid ethyl ester 
• 421595-79-1 imidazo[1,2-a]pyridine-7-carbonyl azide 
• 808744-34-5 7-bromoimidazo[1,2-a]pyridine 
• 84249-14-9 2-amino-4-bromopyridine 
• 4532-25-6 7-chloroimidazo-[1,2-a]pyridine 
• 421595-78-0 imidazo[1,2-a]pyridine-7-carbohydrazide 

Downstream Products

• 421595-95-1 8-ethyl-9-methylimidazo[2,1-f][1,6]naphthyridine 
• 421595-87-1 N-(triphenyl-λ⁵-phosphanylidene)imidazo[1,2-a]pyridin-7-amine 
• 1362752-18-8 2-cyano-1-(imidazo[1,2-a]pyridin-7-yl)-3-(4-(phenylsulfonyl)benzyl)guanidine 
• 1375110-61-4 9-(3',4',5'-trimethoxyphenyl)imidazo[2,1-f][1,6]naphthyridin-10(7H)-one 
• 1375110-73-8 N-imidazo[1,2-a]pyridin-7-yl-3-oxo-3-phenylpropanamide 
• 1093209-62-1 C₂₂H₂₂ClN₅O₂ 
• 1229384-42-2 3-[3-(4-fluoro-phenoxy)-benzyl]-piperidine-1-carboxylic acid imidazo[1,2-a]pyridin-7-ylamide 

Relevant articles and documents

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

Substituted heteroaryl compounds and compositions and uses thereof (by machine translation)

The invention discloses substituted heteroaryl compounds and compositions thereof and their use. The compounds of formula (I) compound or type shown in (I) a compound represented by stereo isomers, tautomers, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or its prodrug. The invention also provides a pharmaceutical composition, the compounds and pharmaceutical compositions can be regulated protein kinase, particularly Aurora kinase and JAK kinase activity, for the prevention, treatment, treatment and reduce protein kinase, in particular JAK kinase activity mediated diseases or disorders. (by machine translation)

Oxalic amide ligands, and uses thereof in copper-catalyzed coupling reaction of aryl halides

The present invention provides oxalic amide ligands and uses thereof in copper-catalyzed coupling reaction of aryl halides. Specifically, the present invention provides a use of a compound represented by formula I, wherein definitions of each group are described in the specification. The compound represented by formula I can be used as a ligand in copper-catalyzed coupling reaction of aryl halides for the formation of C—N, C—O and C—S bonds.

HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE

Provided are a heterocyclic carboxylic acid amide ligand and applications thereof in a copper catalyzed coupling reaction. Specifically, provided are uses of a compound represented by formula (I), definitions of radical groups being described in the specifications. The compound represented by formula (I) can be used as the ligand in the copper catalyzed coupling reaction of the aryl halogeno substitute, and is used or catalyzing the coupling reaction for forming the aryl halogeno substitute having C—N, C—O, C—S and other bonds.

Assembly of Primary (Hetero)Arylamines via CuI/Oxalic Diamide-Catalyzed Coupling of Aryl Chlorides and Ammonia

A general and practical catalytic system for aryl amination of aryl chlorides with aqueous or gaseous ammonia has been developed, with CuI as the catalyst and bisaryl oxalic diamides as the ligands. The reaction proceeds at 105-120°C to provide a diverse set of primary (hetero)aryl amines in high yields with various functional groups.

HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE

Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).

HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE

Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).

Aminoimidazo[1,2-a]pyridines: Regioselective synthesis of substituted imidazonaphthyridines, azacarbolines and cyclazines

In order to study the regioselectivity of thermal cyclocondensation, aminoimidazo[1,2-a]pyridines (AIP) 5a-e were prepared, further converted into iminophosphoranes 7a-e, and ultimately converted regioselectively in angular annulated imidazonaphthyridines (IN) 8a, 10a, 11a, 12a or linear annulated dipyridoimidazole (DPI) 17a. From 2-substituted derivative 23, the peri annulated product 24a was obtained. The starting amines 5a-f reacted with aldehydes to yield regioselectively IN 8a-c, 10a-c, 11a-c, 12a,b, DPI 16a-e, 17a-d and TIBO like structures (±)-13 and 24a-c, as proved by X-ray analysis. The 1,2- or 1,4-addition between amines and α,β-unsaturated aldehydes concerning the pyridine and imidazole moieties is discussed in the light of these results.